Johnson & Johnson (NYSE:JNJ) is Legacy Capital Partners Inc.’s 7th Largest Position

Legacy Capital Partners Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 3.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,028 shares of the company’s stock after selling 1,520 shares during the period. Johnson & Johnson makes up about 2.2% of Legacy Capital Partners Inc.’s holdings, making the stock its 7th largest holding. Legacy Capital Partners Inc.’s holdings in Johnson & Johnson were worth $4,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of JNJ. Zions Bancorporation N.A. boosted its position in shares of Johnson & Johnson by 0.4% during the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after buying an additional 73 shares during the period. Vishria Bird Financial Group LLC boosted its position in shares of Johnson & Johnson by 3.0% during the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after buying an additional 80 shares during the period. G&S Capital LLC boosted its position in shares of Johnson & Johnson by 1.8% during the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after buying an additional 84 shares during the period. Deane Retirement Strategies Inc. boosted its position in shares of Johnson & Johnson by 0.7% during the second quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock worth $1,724,000 after buying an additional 85 shares during the period. Finally, Evanson Asset Management LLC boosted its position in shares of Johnson & Johnson by 0.5% during the second quarter. Evanson Asset Management LLC now owns 17,870 shares of the company’s stock worth $2,489,000 after buying an additional 85 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

JNJ has been the subject of several research analyst reports. Credit Suisse Group raised their price target on Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Raymond James lowered their price target on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Finally, Morgan Stanley restated an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and an average target price of $151.64.

Shares of NYSE JNJ opened at $127.50 on Friday. The stock has a market cap of $342.83 billion, a P/E ratio of 15.59, a PEG ratio of 2.19 and a beta of 0.69. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The business’s fifty day simple moving average is $130.50 and its 200-day simple moving average is $134.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the firm earned $2.05 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is currently 46.45%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Options Trading – Understanding Strike Price

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.